Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEnquest Regulatory News (ENQ)

Share Price Information for Enquest (ENQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.22
Bid: 16.24
Ask: 16.28
Change: 0.36 (2.27%)
Spread: 0.04 (0.246%)
Open: 16.60
High: 16.60
Low: 15.74
Prev. Close: 15.86
ENQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Supplementary Prospectus

5 Oct 2021 17:07

RNS Number : 1129O
EnQuest PLC
05 October 2021
 

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL BE CONSTRUED AS AN OFFER, INVITATION OR RECOMMENDATION TO PURCHASE, SELL OR SUBSCRIBE FOR ANY SECURITIES IN ANY JURISDICTION AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY INVESTMENT ACTIVITY.

ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF ANY SECURITIES REFERRED TO IN THIS ANNOUNCEMENT MUST BE MADE SOLELY ON THE BASIS OF THE INFORMATION THAT IS CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS AND THE SUPPLEMENTARY PROSPECTUS PUBLISHED BY THE COMPANY TODAY AVAILABLE, SUBJECT TO CERTAIN EXCEPTIONS, ON THE COMPANY'S WEBSITE, WWW.ENQUEST.COM.

FOR IMMEDIATE RELEASE.

 

5 October 2021

 

EnQuest PLC

 

Publication of Supplementary Prospectus

 

The Board of EnQuest PLC ("EnQuest", or the "Company") announces that, having received approval from the Financial Conduct Authority (the "FCA"), the Company has published a supplementary prospectus (the "Supplementary Prospectus"). The Supplementary Prospectus is supplemental to, and should be read in conjunction with, the joint circular and prospectus (the "Prospectus") published by the Company on 30 June 2021 in relation to, amongst other things, the proposed re-admission of the entire issued share capital of the Company to the premium listing segment of the Official List and to trading on London Stock Exchange plc's main market for listed securities ("Re-admission") following completion of the acquisition of a 26.69% non-operated equity interest in the Golden Eagle Area Development, which constitutes a reverse takeover for the purposes of the FCA's Listing Rules (the "Acquisition").

 

The Supplementary Prospectus is a regulatory requirement under the UK Prospectus Regulation Rules following the publication of restated 2020 financials, which reflected the discovery of an inconsistency in the calculation of the deferred tax asset recognised on the balance sheet dated 31 December 2020 totaling US$155.9 million, as part of its 2021 interim report.

 

A copy of the Supplementary Prospectus will be submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The Supplementary Prospectus will also be available on the Company's website at: https://www.enquest.com, subject to certain exceptions.

For more information, please contact:

EnQuest PLC Tel: +44 (0)20 7925 4900

Amjad Bseisu (Chief Executive)

Jonathan Swinney (Chief Financial Officer)

Ian Wood (Head of Communications & Investor Relations)

Jonathan Edwards (Senior Investor Relations & Communications Manager)

 

J.P. Morgan Cazenove Tel: +44 (0)20 7742 4000

Jamie Riddell

Barry Meyers

Fraser Jamieson

 

Tulchan Communications Tel: +44 (0)20 7353 4200

Martin Robinson

Martin Pengelley

Harry Cameron

 

IMPORTANT INFORMATION

This announcement has been issued by and is the sole responsibility of the Company.

This announcement is for information purposes only and is not intended and does not constitute or form part of any offer or invitation to purchase or subscribe for, or any solicitation to purchase or subscribe for, any securities of the Company in any jurisdiction. No public offering of securities is being made in any such jurisdiction.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, or under the securities laws or with any securities regulatory authority of any state or other jurisdiction of the United States, and accordingly may not be offered, sold, pledged or transferred, directly or indirectly, in, into or within the United States. There is no intention to register any portion of any offering in the United States or to conduct a public offering of securities in the United States.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required by the Company and J.P. Morgan Cazenove to inform themselves about and to observe any such restrictions. Any failure to comply with this restriction may constitute a violation of the securities laws of such jurisdictions.

J.P. Morgan Securities plc (which conducts its UK investment banking activities as J.P. Morgan Cazenove) ("J.P. Morgan Cazenove") is authorized by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the FCA and the PRA. J.P. Morgan Cazenove is acting exclusively for the Company and no one else in connection with the Acquisition, Re-admission or any other matter referred to in this announcement and will not be responsible to anyone other than the Company for providing the protections afforded its clients nor for providing advice in relation to the Acquisition, Re-admission or any other matter referred to in this announcement.

Save for the responsibilities and liabilities, if any, which may be imposed on J.P. Morgan Cazenove by FSMA or by the regulatory regime established under the Financial Services and Markets Act 2000, as amended, neither J.P. Morgan Cazenove nor any of its affiliates, directors, officers, employees, agents or advisers accepts any duty, liability or responsibility whatsoever (whether direct or indirect) to any person for, or makes any representation or warranty, express or implied, as to the contents of this announcement, including its accuracy, completeness, sufficiency or verification, or for any other statement made or purported to be made by or on its behalf in connection with the Company, the Acquisition or Re-admission and nothing in this announcement will be relied upon as a promise or representation in this respect, whether or not as to the past, present or future. J.P. Morgan Cazenove and each of its affiliates, directors, officers, employees, agents or advisers accordingly disclaim, to the fullest extent permitted by law, all and any duty, liability and responsibility whatsoever, whether direct or indirect, whether arising in tort, contract, under statute or otherwise (save as referred to above) in respect of this announcement or any such statement or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPMABFTMTMMBJB
Date   Source Headline
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20247:00 amRNSTransaction in Own Shares
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 202410:25 amRNSDirector/PDMR Shareholding
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20243:00 pmRNSAnnual Financial Report
28th Mar 20247:01 amRNSResults for the year ended 31 December 2023
28th Mar 20247:00 amRNSDirectorate Change
28th Feb 202411:22 amRNSTotal Voting Rights
15th Feb 20247:00 amRNSFebruary Operations Update
30th Jan 202410:00 amRNSTermination of reporting issuer status in Canada
28th Dec 202310:01 amRNSTotal Voting Rights
22nd Dec 20237:00 amRNSSale of 15% of Bressay and EnQuest Producer FPSO
20th Dec 20234:46 pmRNSHolding(s) in Company
18th Dec 20234:00 pmRNSDirector Change
11th Dec 202311:34 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSDirectorate Change - EnQuest New Energy Leadership
5th Dec 20233:30 pmRNSConfirmation of delisting date
5th Dec 20239:30 amRNSSubmission of delisting application
4th Dec 20235:34 pmRNSDirector/PDMR Shareholding
28th Nov 20237:00 amRNSEnQuest November Operations Update
24th Nov 20239:00 amRNSApplication for Block Listing
30th Oct 20234:50 pmRNSDirector/PDMR Shareholding
30th Oct 20232:00 pmRNSNasdaq Stockholm delisting update
28th Sep 20233:00 pmRNSHolding(s) in Company
26th Sep 202310:03 amRNSPDMR Notification
13th Sep 202311:04 amRNSDirectorate Change
5th Sep 20237:02 amRNSNasdaq Stockholm delisting application
5th Sep 20237:01 amRNSBoard appointment
5th Sep 20237:00 amRNSHalf-year Results
25th Aug 20232:09 pmRNSTerm loan facility agreement
19th Jul 20232:20 pmRNSDirector/PDMR Shareholding
22nd Jun 202312:06 pmRNSReport on Payments to Govts
6th Jun 20239:02 amRNSResult of AGM
5th Jun 20233:00 pmRNSHolding(s) in Company
24th May 20237:00 amRNSEnQuest May Operations Update
18th May 20232:30 pmRNSEnQuest awarded offer of carbon storage licences
9th May 20237:00 amRNSEnQuest Malaysia Update
28th Apr 20232:00 pmRNSNotice of AGM
25th Apr 20239:00 amRNSAnnual Financial Report
13th Apr 20234:54 pmRNSDirectorate Change
5th Apr 20237:00 amRNSResults for the year ended 31 December 2022
17th Mar 20237:00 amRNS2022 Preliminary Results - revised date
15th Mar 202311:00 amRNSHolding(s) in Company
17th Feb 20237:00 amRNSTrading Statement
20th Dec 20221:35 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSChairman succession
24th Nov 20227:00 amRNSOperations Update
26th Oct 20227:00 amRNSSuccessful refinancing of capital structure
13th Oct 20227:00 amRNSPricing of new bond issue

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.